Viva Biotech Holdings · HKEX:1873
Viva Biotech — H1 2026 Earnings Presentation
32 slides from Viva Biotech's earnings presentation, Aug 27, 2026
Slide 1: Viva Biotech 2026 Interim Results Conference
Viva Biotech 2026 Interim Results Conference Date: August 27, 2026 (Thursday) Language: English
Slide 2: Forward-Looking Statements; Non-IFRS
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Content
CONTENT 01 Business Highlights 02 Financial Performance 03 Future Strategies Q&A Session
Slide 4: Part 1: Business Highlights
CV iva PART 1: Business Highlights
Slide 5: World Leading One-stop Innovative Original Drug R&D and Production Platform
World Leading One-stop Innovative Original Drug R&D and Production Platform CDMO Research and EFS Investment and CRO Business Production Business Incubation Business Focus on FIC's Discover business, take Provide innovative drug partners with small Focus on discovering and investing SBDD as the core
Slide 6: Equity Structure of Viva Biotech
Equity Structure of Viva Biotech Viva Biotech Holdings (1873.HK) 10.87% Strategic investors 26.34% 72.9% 100% 100% Small Molecule Incubator CRO CDMO 100% 100% 100% Onshore Offshore Shanghai Jiaxing Suzhou Chengdu Overseas Shanghai Ningbo Taizhou Equity Incubators Equity Holding Holding Platform Plat
Slide 7: Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services
Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services One-stop R&D Service Platform for Innovative Novel Drugs Affinity-Based Drug Screening Peptides Protein and Mass Spectrometry (ASMS, INTACT-MS) SPR Drug Oligo Nucleotides Crystal Soaking Metabolism （PPO） Protein Scien
Slide 8: Overview: Business Highlights
Overview Business Highlights Revenue in 2026H1 reached RMB1006.5 million, +21.0% YoY, +25.1% YoY on RMB Million a constant exchange rate. 2000 50.0% Gross profit reached RMB341.7 million, +0.7% YoY, +10.7% YoY on a constant 1800 1729.4 40.8% 45.0% exchange rate. 1600 37.9% Gross profit margin:
Slide 9: CRO Business: Revenue Growth Expected to Gradually Recover
Business Highlights CRO Business：Revenue Growth Expected to Gradually Recover, Primarily Affected by Adverse Foreign-Exchange Movements in the Short Term Revenue: RMB405.1 million, -4.2% YoY, -1.2% YoY on a constant exchange rate. Adjusted gross profit: RMB173.7 million, -10.7% YoY, -2.6% YoY on
Slide 10: CRO Business: R&D Headcount Recovering, Client Base Expanding
CRO Business：R&D Headcount Steadily Recovering, With Client Base Continuing to Expand Served Top 50 Global R&D Headcount Steadily Recovering and Increasing Pharmaceutical Companies 2026H1 1155 2025 1123 2025H1 1098 Based on Total Annual Revenue in 2026H1 Number of CRO Clients: +18.9% YoY Multiple cl
Slide 11: CRO Business: AI Technology Facilitates R&D of Novel Targets
CRO Business： AI Technology Facilitates the R&D of Novel Targets, Continuous Increase in Deliveries of Novel Targets and Protein Structures AI Drives Continuous Growth in Delivered Novel Synchrotron Radiation Source Utilization Efficiency Targets and Protein Structures Steadily Improving, Operating
Slide 12: AI Technology Driven Experiments Pave the Way for a New Era in Drug Development
AI Technology Driven Experiments Pave the Way for a New Era in Drug Development AI-Empowered Integrated Platform Transforms R&D Paradigm AI Design Build & test Optimized lead CMC GMP supply Proprietary AI & integrated dry–wet closed loop: proven track record driving end-to-end delivery 「Talent Found
Slide 13: MARS Enables Cross-Modality, End-to-End Drug Discovery
MARS Enables Cross-Modality, End-to-End Drug Discovery Target Discovery Hit Identification Lead Optimization Drug Candidate End-to-End PCC R Mol2MARS Pep2MARS Ab2MARS BiF2MARS O Small Molecules Peptide Antibody Bi-functionals Multi- 300K+ Library for Virtual In-house Epitope Prediction Epitope
Slide 14: Pep2MARS: AI-Driven Peptide Drug Discovery Platform
Pep2MARS——AI-Driven Peptide Drug Discovery Platform PCC Selection DMPK Pharmacology Non-GLP tox Target 5 Lead Optimization 1 4 AI-guided rational design High throughput peptide/cyclic Target types and interaction peptide synthesis mechanisms Biophysical/Biochemical/Cell assays Early DMPK evaluation
Slide 15: Business Highlights: CDMO R&D and Production Services
Business Highlights CDMO R&D and Production Services Revenue of Langhua: RMB601.4 million, +47.0% YoY, +52.2% YoY on a constant RMB Million exchange rate. Adjusted gross profit of Langhua: RMB175.1 million, +12.9% YoY, +26.5% YoY on a constant exchange rate. Adjusted gross profit margin of Lan
Slide 16: CDMO Business: Commercial Manufacturing Scale-Up Driving Revenue Growth
CDMO Business: Commercial Manufacturing Scale-Up Driving Revenue Growth and Capacity Construction Steadily Advance CDMO Business: Entering a Phase of Accelerated Growth RMB Million +75.4% YoY 434.9 248.0 122.5 147.4 2025H1 2026H1 Revenue Adjusted Gross Profit Revenue from CDMO: RMB 434.9 million,
Slide 17: Optimized CMC Operations, Achieving a Turnaround from Loss to Profitability
Optimized CMC Operations, Achieving a Turnaround from Loss to Profitability Constant Increase in the Number of CMC Projects The Overall CMC R&D Staff Remain Stable Projects Persons 2026H1 320 2026H1 107 2025 295 2025 96 2025H1 279 2025H1 100 • The Group established a new PPO business unit and will c
Slide 18: Business Highlights: EFS Investment & Incubation Business
Business Highlights EFS Investment & Incubation Business RMB Million As the end of the reporting period，the Group has invested a total of 93 portfolio companies. 1575.2 1593.2 During the reporting period ， several portfolio companies achieved exits ， 1469.8 1207.5 1208 generating aggregate cash
Slide 19: VBI Investment Exits and Components Overview
VBI Investment Exits and Components Overview As of 2026H1，VBI has invested in a total of 93 portfolio companies. The Group has successfully realized 19 investment exits or partial exits, and the enterprises invested in the incubation covered multiple indications, multiple molecular models and mult
Slide 20: Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress
Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress • In May 2026, Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout. 232 Pipeline Projects in Portfolio Companies • In May 2026, Full-Life Technologies announces US$150 million *Calculated Bas
Slide 21: Key Projects in VBI Investment Portfolio
Key Projects in VBI Investment Portfolio No. Name Country Mechanism Indication Pipeline Company Overview A clinical-stage biotechnology company developing therapeutics for gout and chronic kidney disease. Its proprietary drug candidate, AR882, has Small Gout and 1 Arthrosi USA Molecule Tophus Clinic
Slide 22: Part 2: Financial Performance
PART 2: Financial Performance
Slide 23: Group Financial Performance: Solid Revenue & Net Profit Growth
Group Financial Performance: Solid Revenue & Net Profit Growth Revenue of the Group Experienced a Significant YoY Increase Group Gross Profit Experienced a YoY Increase RMB million +21.0% YoY RMB million +0.7% YoY 1006.5 831.9 339.4 341.7 2025H1 2026H1 2025H1 2026H1 Note：under a constant exchange ra
Slide 24: CRO Financial Statistics
CRO Financial Statistics: Primarily Impacted by Unfavorable Currency Movements, With Recovery Expected in 2026H2 CRO Revenue RMB million Adjusted Gross Profit RMB million 422.8 405.1 194.6 173.7 2025H1 2026H1 2025H1 2026H1 Note：under a constant exchange rate, CRO revenue -1.2% YoY Note：under a const
Slide 25: CDMO Financial Statistics: Rapid Revenue Growth
CDMO Financial Statistics: Rapid Revenue Growth Driven by Ramp-Up of Commercial Products Langhua Adjusted Gross Margin Expected to Improve as the Revenue and Adjusted Gross Profit of Langhua RMB million Industrial Chain Shifts Upstream Going Forward +47.0% YoY 601.4 37.9% 409 29.1% 175.1 155.1 2025H
Slide 26: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities As at June 30, 2026 CDMO and commercialization Drug discovery services VBI Total service Types of goods or services RMB’000 RMB’000 RMB’000 RMB’000 Revenue from non-investees Full-time-equivalent (FTE) 303,145 - - 303,145 Fee-for-service (FFS) 95,111 1
Slide 27: Items Measured at Fair Value with Changes Recognized in Profit or Loss
Items Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows ： RMB’000 January 1, 2026 829,047 Recognized from SFE revenue 489 Gain on fair value change 31,577 Disposa
Slide 28: Appendix: Adjusted Non-IFRS Net Profit
APPENDIX: Adjusted Non-IFRS Net Profit 2026H1 2025FY 2025H1 2024FY 2024H1 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Net Profit / (Loss) 100,879 269,267 148,637 221,987 144,237 Add: Fair Value Gain on Financial Liabilities at FVTPL - - - Add: interest expenses of the debt components of the - - Converti
Slide 29: Part 3: Future Strategies
CV iva PART 3: Future Strategies
Slide 30: Improve Capacity Building for Front-end Projects, Expand Whole Industry Chain Service
Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream To Establish an Open and Cooperative Platform and a Win-win Ecosystem for Global Biopharmaceutical Innovators Early-stage preclinical service Raise technology barriers and expand servic
Slide 31: Q&A Session
CV iva Q&A Session
Slide 32: Viva Biotech Holdings
Viva Biotech Holdings No.735, Ziping Road, Pudong New Area, Shanghai 201318, China —— Tel: +86 21 6089 3288 E-mail: info@vivabiotech.com www.vivabiotech.com
Viva Biotech Holdings — H1 2026 Earnings Presentation on 6ix